NCT06220773

A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy

A Randomized, Double-blind, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy in Patients With Essential Hypertension and Type 2 Diabetes Mellitus

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 276 (estimated)
• Sponsor: Boryung Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

The objective of this clinical study is to Evaluate the Efficacy and Safety of BR1019A and BR1019B combination therapy in Patients with Essential Hypertension and Type 2 Diabetes Mellitus

Conditions

• Essential Hypertension
• Type 2 Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	BR1019A	Subjects take the investigational products once a day for 12 weeks.
DRUG	BR1019B	Subjects take the investigational products once a day for 12 weeks.
DRUG	BR1019C	Subjects take the investigational products once a day for 12 weeks.
DRUG	BR1019A-1	Subjects take the investigational products once a day for 12 weeks.
DRUG	BR1019B-1	Subjects take the investigational products once a day for 12 weeks.
DRUG	BR1019C-1	Subjects take the investigational products once a day for 12 weeks.

Timeline

• Start date: 2024-05-21
• Primary completion: 2025-04-01
• Completion: 2025-04-01
• First posted: 2024-01-24
• Last updated: 2024-05-22

Locations

2 sites across 1 country: South Korea